All Stories

  1. Magnetic Resonance Imaging-negative Encephalomyeloradiculopathy Diagnosed by Anti-lactosylceramide Antibody Positivity and Electrophysiological Findings: A Case Report and Review of the Literature
  2. Pediatric Encephalomyeloradiculoneuropathy With High Lactate in Cerebrospinal Fluid and Magnetic Resonance Spectroscopy: A Case Report
  3. Elevated TFEB expression with limited activation in peripheral blood mononuclear cells reflects altered lysosomal enzyme dynamics in Parkinson's disease
  4. Cerebrospinal fluid sphingolipid and sterol metabolite profiles of neurologically normal subjects
  5. Effective relapse prevention with monthly intravenous immunoglobulin therapy in a pediatric patient with anti-neutral glycolipid antibody-positive Encephalomyeloradiculoneuropathy
  6. Activation of α7 nicotinic acetylcholine receptor augments nerve growth factor action on PCtrk cells
  7. Increase in Adult Patients with Varicella Zoster Virus–Related Central Nervous System Infections, Japan
  8. Uric acid and alterations of purine recycling disorders in Parkinson’s disease: a cross-sectional study
  9. Enzymatic properties and clinical associations of serum alpha‐galactosidase A in Parkinson's disease
  10. Sphingolipid abnormalities in encephalomyeloradiculoneuropathy (EMRN) are associated with an anti‐neutral glycolipid antibody
  11. A pilot study assessing sphingolipids and glycolipids dysmetabolism in idiopathic normal pressure hydrocephalus
  12. Ceramides accumulation and complement activation in patients with EMRN
  13. Piroheptine for Treating Parkinson
  14. Mazaticol for Treating Parkinson
  15. Acknowledgments
  16. Detection of human herpesviruses in cerebrospinal fluids collected from patients suspected of neuroinfectious diseases
  17. Detection of circulating tumor DNA in cerebrospinal fluid prior to diagnosis of spinal cord lymphoma by flow cytometric and cytologic analyses
  18. Corrigendum to “Galabiosylceramide is present in human cerebrospinal fluid”
  19. Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment
  20. Review article for the close relationship between neuroinflammation and glycosphingolipids
  21. Galabiosylceramide is present in human cerebrospinal fluid
  22. Clioquinol kills astrocyte-derived KT-5 cells by the impairment of the autophagy–lysosome pathway
  23. Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome
  24. cross-talk between Trk neurotrphin receptor and innate immunity
  25. Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease
  26. Mazaticol for Treating Parkinson
  27. Better neuroradiological approach for the diagnosis of early-stage Parkinson's disease patients
  28. Piroheptine for Treating Parkinson
  29. Altered regulation of serum lysosomal acid hydrolase activities in Parkinson's disease: A potential peripheral biomarker?
  30. A Patient With Thiamine Deficiency Exhibiting Muscle Edema Suggested by MRI
  31. Changes in Serial D-Dimer Levels Predict the Prognoses of Trousseau's Syndrome Patients
  32. Anti-GM1 ganglioside antibodies modulate membrane-associated sphingomyelin metabolism by altering neutral sphingomyelinase activity
  33. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study
  34. Usefulness of combining 123 I-FP-CIT-SPECT striatal asymmetry index and cardiac 123 I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms
  35. MR neurography for the evaluation of CIDP
  36. Differentiation of cancer from atrial fibrillation in patients with acute multifocal stroke
  37. encephalomyeloradiculoneuropathy patient showing anti-neutral glycolipids antibodies and epilepsy
  38. brain abscess
  39. Retrospective analysis of parkinsonian patients exhibiting normal 123I-MIBG cardiac uptake
  40. Voriconazole-responsive Disseminated Nodular Lesions on Spinal MRI
  41. Neurotropin promotes NGF signaling through interaction of GM1 ganglioside with Trk neurotrophin receptor in PC12 cells
  42. Hypertrophic pachymeningitis and encephalitis in a patient with relapsing polychondritis
  43. An update on diagnostic imaging studies for viral encephalitis
  44. Winged scapula in patients with myotonic dystrophy type 1
  45. Extracorporeal Aβ removal system (EARS) for Alzheimer's disease therapy: Novel devices with fragments of hollow fibers removed Aβ effectively both in vitro and in vivo
  46. Glycobiology and neurological disorders
  47. Transient Splenial Lesion of the Corpus Callosum in H1N1 Influenza Virus-Associated Encephalitis/Encephalopathy
  48. Neurotrophin Levels in Cerebrospinal Fluid of Adult Patients with Meningitis and Encephalitis
  49. Stimulated neuronal expression of brain-derived neurotrophic factor by Neurotropin
  50. Novel therapeutic approach for Alzheimer’s disease by removing amyloid β protein from the brain with an extracorporeal removal system
  51. Muscle MRI in Myotonic Dystrophy Type 1 with Foot Drop
  52. Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells
  53. Toward the novel method of treatment for Alzheimer's disease: Extra-corporeal Aβ removal system (EARS)
  54. Electroretinograms in three cases of Creutzfeldt-Jakob disease with visual disturbances
  55. Acute Autonomic, Sensory and Motor Neuropathy: Successful Treatment with IVIg
  56. β-amyloid (25–35) enhances lipid metabolism and protein ubiquitination in cultured neurons
  57. Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
  58. Postinfectious Myeloradiculoneuropathy With Cranial Nerve Involvements Associated With Human Herpesvirus 7 Infection
  59. Impairment of Trk-Neurotrophin Receptor by the Serum of a Patient With Subacute Sensory Neuropathy
  60. Abnormal intracellular trafficking of high affinity nerve growth factor receptor, Trk, in stable transfectants expressing presenilin 1 protein
  61. Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts
  62. Biological Implication of the Membrane Rafts in Neuronal Cells
  63. Spinal Cavitous Hemorrhagic Infarction with Abdominal Aortic Aneurysm
  64. HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, Trk, and morphological differentiation with fatal outcome in PC12 cells
  65. Posterior Thoracic Spinal Cord Infarction: Complication of Thoracoabdominal Aortic Aneurysm
  66. MRI findings of benign monomelic amyotrophy of lower limb
  67. Role of tyrosine phosphorylation of phospholipase C γ1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts
  68. Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts
  69. Expression of GDNF receptor (RET and GDNFR-α) mRNAs in the spinal cord of patients with amyotrophic lateral sclerosis
  70. Influence of endogenous GM1 ganglioside on TrkB activity, in cultured neurons
  71. HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway
  72. Differential signaling cascade of MAP kinase and S6 kinase depends on 3′,5′-monophosphate concentration in Schwann cells: correlation to cellular differentiation and proliferation
  73. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule:
  74. GM1 gangliosidosis type 3 with severe jaw-closing impairment
  75. Chorea-acanthocytosis with polyclonal antibodies to ganglioside GM1
  76. Discovery of ganglioside GM1 for normal function of Trk neurotrophin receptor in neuronal cells.
  77. 1-Methyl-4-phenylpyridinum kills differentiated PC12 cells with a concomitant change in protein phosphorylation
  78. Abundant but Inactive-state gpl40prototrkIs Expressed in Neuroblastomas of Patients with Good Prognosis
  79. The Effect of the B Subunit of Cholera Toxin on the Action of Nerve Growth Factor on PC12 Cells
  80. A microassay for acid β-galactosidase activity toward asialofetuin
  81. Application of a GM1 ganglioside β-galactosidase microassay method to diagnosis of GM1 gangliosidosis
  82. A fluorometric microassay procedure for monitoring the enzymatic activity of GM1-ganglioside β-galactosidase by use of high-performance liquid chromatography